11th Annual Meeting of International Cytokine & Interferon Society

第十一届国际细胞因子年会

• 批准号: 10753947
• 负责人: James K Turkson
• 金额: $ 0.5万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-15 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10753947
• 关键词: Allergic Disease; Amaze; Applications Grants; Applied Research; Arthritis; Authorization documentation; Autoimmune Diseases; Autoimmunity; Award; B-Lymphocytes; Basic Science; Biological Markers; Biology; Biotechnology; Budgets; COVID-19; COVID-19 impact; Chronic Disease; Clinic; Clinical Research; Collaborations; Communicable Diseases; Country; Cytokine Network Pathway; Data; Development; Diabetes Mellitus; Discipline; Disease; Event; Feedback; Financial Support; Future; Goals; Government; Greece; HIV; Hawaii; Health; Host Defense; Human; Hybrids; Immune; Infection; Inflammation; Inflammatory; Institution; Interferons; International; Intuition; Kidney Diseases; Knowledge; Lightning; Lobbying; Long COVID; Love; Malignant Neoplasms; Mediating; Modern Medicine; Molecular; Natural Immunity; Parents; Participant; Persons; Pharmacologic Substance; Proteins; Qualifying; Reporting; Research; Research Personnel; Rheumatoid Arthritis; Role; Scientist; Societies; Students; T-Lymphocyte; Therapeutic; Time; Translational Research; Travel; Underrepresented Minority; Update; Vaccination; Viral Cancer; Virus Diseases; Work; adaptive immunity; cancer immunotherapy; career; career development; collaborative environment; cost; cytokine; design; digital platform; exhibitions; flexibility; fundamental research; immune activation; immunoregulation; inhibitor; interest; live stream; meetings; multidisciplinary; new therapeutic target; novel; novel therapeutic intervention; novel therapeutics; personalized medicine; posters; precision medicine; programs; response; symposium; targeted cancer therapy; therapeutic target; virtual; virtual platform

ABSTRACT The purpose of this application is to request financial support for Cytokines 2023: 11th Annual Meeting of the International Cytokine & Interferon Society (ICIS), October,15-18, 2023, with llivestream and on-demand virtual access through October 29, 2023. This Annual Meeting helps bridge the gap between the scientists performing basic research on molecular and cellular mechanisms of immune cell activation and function with those working to develop this knowledge into novel therapies. The 11th edition comes at a time when cytokine biology, cytokine biomarkers and cytokine therapeutics are revolutionizing modern medicine, providing novel treatments for a wide variety of diseases ranging from lethal inflammatory, autoimmune and allergic diseases, to viral infections and cancer. This year’s theme is “Cytokines and interferons in the precision medicine era”, focusing on the latest developments on cytokine biology in relation to immune regulation, host damage and disease, and the latest progress on cytokines/cytokine inhibitors as novel therapeutics in the clinic. A variety of topics will be covered by leaders in the field in the plenary and parallel sessions such as innate immunity and host defense, adaptive immunity, cytokines in T and B cell responses to vaccination, in Long COVID, HIV and novel targeted therapies from cancer immunotherapy to novel therapeutics in autoimmunity. Since a major goal of the meeting is to promote interactions between scientists and clinicians working in basic, translational or applied research, ample opportunity will be given to poster networking sessions to present the latest advances elated to cytokine research, biomarkers and therapeutics. Greater understanding of mechanisms of disease and novel concepts for therapy have and will continue to emerge from interdisciplinary gatherings where advances can be presented and discussed by established and trainee scientists. The meeting will focus on cytokines in personalized medicine and will provide an opportunity for updates on the development of novel therapeutic interventions in these fields and help spur international collaborations among the meeting participants. Although meeting participants will have primary interests in infectious diseases, cancer and immune-mediated diseases, the program integrates speakers on the periphery of Cytokine and Interferon research to help bridge these disciplines. This interdisciplinary environment is particularly interesting for early career researchers who are not only focused on their own field of research but are beginning to think about the wider implications of their work. Our goal is to increase attendance of early career investigators and trainees and also to achieve higher representation of underrepresented minorities at all levels of career development. Online presentations will consist of livestreamed video presentations for all speakers who give their permission to be recorded, to benefit virtual attendees as well as in-person attendees to access content from parallel sessions or missed presentations. ICIS Meetings Committee and Council have decided that included virtual access even without travel restrictions, makes the Annual Meeting more inclusive and sustainable.

摘要 本申请的目的是请求为细胞因子2023：第11届年会提供资金支持 国际细胞因子和干扰素协会(ICIS)，2023年10月15日至18日，提供直播流和按需虚拟 访问截止日期为2023年10月29日。这一年度会议有助于弥合科学家之间的差距 免疫细胞激活与功能的分子和细胞机制基础研究 将这些知识发展成新的治疗方法。第11版是在细胞因子生物学、细胞因子 生物标志物和细胞因子疗法正在给现代医学带来革命性的变化，为广泛的 各种疾病，从致命性炎症、自身免疫和过敏性疾病到病毒感染和 癌症。今年的主题是《精准医学时代的细胞因子和干扰素》，重点关注最新 细胞因子生物学与免疫调节、宿主损伤和疾病的研究进展及最新进展 细胞因子/细胞因子抑制剂作为临床新药的研究进展。 该领域的领导人将在全体会议和平行会议上讨论各种主题，如先天 免疫和宿主防御、获得性免疫、T和B细胞对疫苗的反应中的细胞因子 COVID，HIV和从癌症免疫治疗到自身免疫新疗法的新靶向治疗。 由于会议的一个主要目标是促进科学家和临床医生之间的互动， 翻译或应用研究，将有充分的机会张贴网络会议，介绍 最新进展涉及细胞因子研究、生物标记物和治疗学。对机制有更深入的了解 疾病和治疗的新概念已经并将继续从跨学科聚会中涌现出来 在那里，成熟的和实习的科学家可以介绍和讨论进展。 会议将聚焦于个性化医学中的细胞因子，并将提供一个机会来更新 在这些领域开发新的治疗干预措施，并帮助促进 会议参与者。尽管与会者的主要兴趣是传染病、癌症 和免疫介导的疾病，该程序集成了细胞因子和干扰素外围的扬声器 帮助搭建这些学科之间桥梁的研究。这种跨学科的环境对于早期来说特别有趣 职业研究人员不仅专注于自己的研究领域，而且开始考虑 他们的工作的更广泛的影响。我们的目标是增加早期职业调查人员和实习生的出勤率，并 也是为了使任职人数不足的少数群体在职业发展的各个层面都有更高的代表性。 在线演示文稿将包括为所有获得许可的演讲者提供的实时视频演示文稿 要录制，以使虚拟与会者和面对面与会者能够从Parly访问内容 会议或错过演示文稿。ICIS会议委员会和理事会已决定将虚拟 即使没有旅行限制也可以进入，使年会更具包容性和可持续性。